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Despite the increasingly high rate of implantation of cardioverter-defibrillators (ICD) in elderly patients, data supporting their clinical and cost-
effectiveness in this age stratum are ambiguous and contradictory.We comprehensively reviewed the state-of-the-art data regarding the applic-
ability, safety, clinical- and cost-effectiveness of the ICD in elderly patients, and analysedwhich patients in this age stratum aremore likely to get a
survival benefit from this therapy. Although peri-procedural riskmay be slightly higher in the elderly, this procedure is still relatively safe in this age
group. In terms of correcting potentially life-threatening arrhythmias, the effectiveness of ICD therapy is comparable in older and younger indi-
viduals. However, the assumptionof persistent ICDbenefit in the elderly population is questionable, as any advantage of the deviceon arrhythmic
deathmaybe largely attenuatedbyahigher total non-arrhythmicmortality.While septuagenarians andoctogenarians havehigher annual all-cause
mortality rates, ICD therapy may remain effective in highly selected patients at high risk of arrhythmic death and with minimum comorbidities
despite advanced age. ICD intervention among the elderly, as a group, may not be cost-effective, but the proceduremay reach cost-effectiveness
in those expected to live.5–7years after implantation. Biological age rather than chronological ageper se shouldbe thedecisive factor inmaking
a decision on ICD selection for survival benefit.
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Introduction
Implantable cardioverter-defibrillators (ICDs) are a well-established
therapy for the prevention of sudden cardiac death (SCD).1–7
Studies have shown that.40%of ICDs and cardiac resynchronization
therapy (CRT)devicesare inserted in individuals≥70yearsofage8and
28% of those deemed eligible for ICD implantation by conventional
criteria are octogenarians.9 As the population ages,10,11 the number of
elderly patients considered for ICD implantation is decidedly increas-
ing. However, data supporting the clinical effectiveness of the ICD in
this age stratum are ambiguous and sometimes contradictory.2,12–18
Although guidelines state that ICD implantation is ‘rarely appropriate’
in nonagenarians,19 they do not refer to any specific age limits, but
rather to 1-year life expectancy as a mandatory criterion. Octogenar-
ians in particular constitute an understudied segment of those
potentially eligible for ICD implantation. The few elderly patients
selected for admission into large randomized clinical trials are not
usually representative of the real-world elderly population.
We aimed to comprehensively review the current literature
regarding the potential benefit of ICDs in the elderly and very
elderly population. The applicability of ICD utilization in this age
group, its safety, clinical effectiveness, and cost-effectiveness will be
thoroughly addressed.
Search strategy
Weperformed a comprehensive review of scientific data collectable
from MEDLINE, EMBASE, and COCHRANE (from inception to
May 2014). Studies were selected when addressing the goals of
our review: applicability, safety, clinical, and cost-effectiveness of
ICD implantation in elderly (.70–75 years old) and very elderly
(.80 years old) patients. Qualitative information was extracted
and the reference lists of the accessed full-text articles were
further evaluated for sources of potential information relevant to
this review.
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Rates of cardioverter-defibrillator
implantation in the elderly: are
older patients well represented in
randomized trials and registries?
The average age of patients in the clinical trials of ICDs has been in
60 s, ranging from 50 s to 70 s.1,2 Average age of patients at the time
of study enrolment was between 58–65 years in secondary
prevention trials3 –5 and 58–66 years in the primary prevention
trials.1,2,6,7 Less than 25% of subjects included in the major clinical
ICD trials are estimated to be .75. While most studies included
a very low percentage of octogenarians, others have purposely
excluded patients above the age of 80.1,20,21 As such, prospective
randomized trials are not representative of daily clinical practice. For
this reason, it is not clear whether the survival benefit conferred by
the ICD also extends to older patients with more limited life span
(Table 1).
Data from national or international registries provide a reason-
able estimate of the proportion of ICDs implanted in elderly
patients in real-world clinical practice. Forty-two per cent of the
339.076 ICD implantations included in the United States National
ICD registry over a 3-year period were .70 years old, while
12.4% were older than .80.22 Of the 4.566 patients included
in the Advancements in ICD Therapy Registry after first ICD or
CRT-D implantation, 29% per cent were 70–79 years old, while
12%were.80.8 TheOntario ICDDatabase included 5399 patients
ofwhich 31.6%were aged 70–79 and 8.0%were≥80 years of age.23
Data of patients enrolled in the Italian ICD Registry for the years
2005–07 revealed that the median age of those treated with new
implantation or replacement of ICD was 69 years, with ages
60 and 75 representing quartiles I and III, respectively.24 From
November 1991 to May 2012, 5.3% of 1428 patients admitted for
ICD implantation or generator replacement in our Department
were octogenarians.25
Applicability: sudden cardiac death
and ventricular arrhythmias in the
elderly
An analysis of 6252 patients with structural heart disease has shown
that, although both sudden death and non-sudden death rates in-
creasewith age, the increase of non-sudden death is muchmore dra-
matic and the resultant SCD/all-cause mortality ratio diminishes
progressively with advancing age (from 0.51 before age 50 to 0.26
after age 80). Importantly, age was the only clear-cut predictor of
this change in risk in this patient population.26 An analysis of the
pooled results of all secondary prevention ICD trials (AVID, CIDS,
and CASH), including a total of 1866 patients, of whom 252 were
≥75 years old, has shown that over a mean follow-up of 2.3+ 1.9
years the incidence of death from heart failure or non-cardiac
causes was significantly higher among patients ≥75 years old.18
However, the rate of arrhythmic death was similar between the
two groups, resulting in a much lower relative contribution of SCD
to all-cause mortality in the elderly group. Almost 20% of elderly
patients (≥75 years old) died within 1 year of their episode of life-
threatening ventricular arrhythmias, and at least three-quarters of
these deaths were not potentially preventable by an ICD.18 Grimm
et al.27 followed 500 consecutive ICD patients and concluded that
5-year overall mortality rate was much higher in patients ≥75 vs.
,75 years of age (55 vs. 21%), mostly due to a higher mortality
from heart failure.
However, Yung et al.23 observed that, although elderly patients
showhighermortality rates after ICD implantation, ratesof appropri-
ate shocks are similar across age groups. In this prospective registryof
5399 ICDrecipients, rates of appropriate shocks for primary and sec-
ondary prevention patients .80 years old were 4.2 events and 11.9
events per 100 person-years, respectively, similar to rates seen in
younger patients. Appropriate ICD therapy was successful in ter-
minating the arrhythmia in practically all cases and almost all elderly
patients survived .30 days after the shock. The authors concluded
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Studies evaluating rates of ICD implantation in the elderly
Study Study Design Percentage of elderly
patients
United States National ICD
Registry22
† National registry 2006–08
† 339 076 ICD patients
.70 years old/42%
.80 years old/12.4%
Advancements in ICD
Therapy Registry8
† Prospective 2-year study of largely community-based practice and reporting data from 264
centres in the USA between November 2004 and March 2006
† 4566 ICD/CRT-D patients
70–79 years old/29%
≥80 years old/12%
Ontario ICD Database23 † Population-based prospective registry, February 2007–September 2010
† 5399 ICD patients
70–79 years old/31.6%
≥80 years old/8.0%
Italian ICD Registry24 † Prospective ICD registry for the years 2005–07
† Numberof ICDs permillion of inhabitants: 180.6 in the year 2005, 192.5 in the year 2006, and
220.6 in the year 2007
≥75 years old/25%
Papworth Hospital ICD
Registry25
† Prospective ICD registry, November 1991–May 2012
† 1428 patients admitted for ICD implantation or generator replacement
5.3% octogenarians
ICD, Implantable cardioverter-defibrillator; CRT-D, Cardiac resynchronization therapy defibrillator.
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that they had a similar likelihood of receiving appropriate device
therapy and therefore they could potentially benefit from the ICD as
muchastheir youngercounterparts.23 Inadifferent study, a similar ven-
tricular tachyarrhythmia burden and number of ICD treatment inter-
ventions were observed in 159 patients ,75 years of age vs. 49 who
were ≥75.28 Importantly, a higher mortality rate was seen in the
elderly subgroup, almost exclusively of a non-sudden cardiac basis.28
Thus, in termsof reversingpotentially life-threatening arrhythmias,
the rationale for ICDtherapy is comparable inolderandyounger indi-
viduals. Elderly patients do not seemmore susceptible to unsuccess-
ful shocks or electromechanical dissociation after ICD shock.
However, an evaluation of the potential benefit of the ICD should
not be based on rates of appropriate ICD therapies. Unnecessary,
albeit terminologically appropriate, ICD therapy for non-sustained
VT is an expanding concern and underlines the need for appropriate
ICD programming. In the SCD-HeFT trial, 21% of the patients had
appropriate shocks for fast VT or VF, yet the absolute reduction in
mortality was only 7.2% at 5 years,2 while in the DEFINITE trial
patients in the ICD group experienced twice as many appropriate
shocks than there were fatal events in the control group.29 The
MADIT-RIT study suggested that inappropriate or unnecessary
shocks may in fact potentially increase mortality.30
Safety: do elderly patients carry a
higher risk of peri- and
post-procedural complications?
Primum non nocere!
Tsai et al.31 evaluated the influence of age on perioperative complica-
tions among 150.264 primary prevention ICD recipients. The occur-
rence of any adverse event or in-hospital death increased from 2.8%
in the youngest age group (,65 years of age) to 4.5% in theoldest age
groups (≥80 years). Multivariate analysis found an increased odds of
any adverse event or death among 75–79-year olds (1.14 [95% CI,
1.03–1.25], 80-to 84-year-olds (1.22 [95% CI, 1.10–1.36], and
patients 85 years and older (1.15 [95% CI, 1.01–1.32], compared
with patients under 65 years old. Once patients reached 80 years
of age, the rate of any events, including mortality, reached a plateau
(4.5% in 80–84 year old patients and 4.5% in those ≥85 years old).
Themajority of complications wereminor for all age groups. Import-
antly, comorbid conditions such as renal failure, stage IV heart failure,
atrial fibrillation or 3rd degree heart block were stronger predictors
than age in determining complication risks. Biventricular ICD place-
ment, female gender, physician non-certification and device implant-
ation by non-electrophysiologists were also as important, or even
more so, than age in predicting complications.31 Yung and associates
did not show any increase in the frequency of device-related compli-
cationswithin 45 days of implantation across the different age groups
(except that younger primary prevention patients had higher in-
appropriate shock rates).23 Different studies corroborated these
findings, reporting similar rates of procedure-, lead- and pulse gener-
ator-related complications between different age groups (including
infection, lead failure and lead dislodgement), and a higher risk of in-
appropriate shocks in youngerpatients.27,32–36Two large studies and
a meta-analysis including randomized controlled trial (RCTs) and
observational studies have shown that age is not an independent
risk factor for increased ICD-related, operative, in-hospital, or long-
term complications (Table 2).12,34,35
When referring an elderly patient for ICD implantation, physicians
need to assess their risk of procedural and post-procedural compli-
cations.31 Based on data from 268 701 ICD implants, Haines et al.37
developed a simple risk score consisting of 10 readily available vari-
ables that can accurately identify patients at high and low risk of com-
plications. The risk of any in-hospital complication increased with
increasing scores.
Although complications in new implants are relatively low in
general, theymaybepotentially increasedat the timeof generator re-
placement (4.1–5.8%38,39). However, detailed data on the risks and
predictors of complications in a nationwide cohort in Denmark sug-
gested that ICD generator replacement is less likely to cause compli-
cations than the initial device implantation and, in contrast with
previous reports, age.80yearswas associatedwith a 20%reduction
in complication risk, mostly due to a marked reduction in the fre-
quency of lead-related re-interventions.40
Clinical effectiveness: does the
elderly implantable
cardioverter-defibrillator recipient
live longer?
Estimate of the overall survival in elderly
patients receiving ICDs: interaction age/
survival
Heart failure patients express meaningful preferences about quality
vs. length of life, with younger patients preferring increased survival
whereas older patients often consider quality of life (QoL) of greater
importance.41 Although a discussion of the potential benefit of the
ICD in elderly patients should not be limited to a comparison of mor-
tality rates with vs. without the ICD, all-cause mortality is usually the
most robust and easily assessed endpoint.
Observational studies have previously assessed survival of elderly
patients following ICD implantation,23,33,42,43 whereas the first as-
sessment of survival in octogenarians following ICD generator re-
placement was much more recent.25 Koplan et al.42 reported a
median survival of 4.2 years in 107 primary prevention ICD patients
aged ≥80 years vs. 7 years in 242 sexagenarian ICD recipients.
Patientswith severeLVdysfunction andconcurrent renaldysfunction
had a median survival of only 19 months. Pellegrini et al reported a
median survival of 5.3 years among 120 subjects .75 years old
(24% of cohort) who had transvenous ICD implantation or revision.
After controlling for potential confounders and comorbidities, age at
ICD implantation remained strongly associated with subsequent
total, cardiac, and non-cardiac mortality. Importantly, divergence
in survival occurred early and continued to increase throughout
the follow-up time. The authors concluded that age itself should be
considered a comorbidity when deeming appropriateness of ICD
implantation, as it exerts an effect on mortality independent of base-
line co-morbidity data.43 VanRees et al.33 followed1395primarypre-
vention ICD recipients and reported that, despite comparable rates
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of appropriate shocks between different age groups, almost half of
the patients ≥75 vs. 15% of those ,65 years old died in the first 5
years, and 22% vs. 5%, respectively, died within 1 year following
appropriate therapy. More recent data reported similar findings:
10.2 deaths per 100 person-years in primary prevention octogenar-
ian patients and 15.5 deaths per 100 person-years in secondary pre-
vention octogenarians.23 This study also suggested that death after
appropriate shock is highest among elderly primary and secondary
prevention patients (after an appropriate shock, the adjusted
hazard ratios for death per decade were 1.28 and 1.34 for primary
and secondary prevention, respectively). In our analysis of all
ICD-related procedures carried out in octogenarian patients at our
hospital between November 1991 and May 2012, we found the
median additional years of life after ICD implantation in patients
who died before data retrieval was 2.5, and 65% of deceased patients
after ICD implantation died in the first 3 years after the procedure.25
A different study concluded that mortality of patients ≥75 years old
was similar to that of the age-matched general population irrespect-
ive of delivery of ICD therapy.44Conversely,Duray et al.32 concluded
that elderly ICD recipients had comparable survival rates and appro-
priate use of the ICD compared with younger individuals.
The median survival of elderly ICD recipients should be taken
into account. Taken as a whole, the overall life expectancy of octo-
genarians in the USA is 8 years, which is two-fold greater than that
observed in octogenarian ICD recipients in the study by Koplan
et al.42 Prior data reported 1- and 5-year survival of 80 and 40%, re-
spectively, in octogenarians following pacemaker implantation,45 and
a 1-year mortality of 11.1 and 8.1% for elderly patients (age 75–91)
with chronic coronary artery disease treated invasively or conserva-
tively, respectively.46
Subgroup analyses of themain implantable
cardioverter-defibrillator trials and/or
meta-analyses
Evidence in favour of implantable cardioverter-defibrillator
implantation in the elderly
Asub-groupanalysis of theMADIT-II trial revealed a0.56hazard ratio
(95 CI 0.29–1.08, P ¼ 0.08) for the mortality risk in patients ≥75
years assigned todefibrillator implant comparedwith those in conven-
tional therapy after a mean follow-up of 17.2 months (comparatively,
the hazard ratio in patients ,75 years assigned to defibrillator
implantwas0.63 after 20.8months,CI 0.45–0.88,P ¼ 0.01).13 Fewdif-
ferences in sub-group characteristicswereobservedbetweenpatients
,75 and ≥75 years old, suggesting a highly careful selection of elderly
patients qualifying for ICD treatment. It is noteworthy that, in the ori-
ginal MADIT-II trial, the survival curves between ICD and medical
therapy-only subjects did not begin to diverge until 9 months after
implant.1 In a prospective cohort study of 965 patients with ischaemic
and non-ischaemic cardiomyopathies, severe LV dysfunction and
no prior ventricular arrhythmias, a comparison was made between
long-term mortality in patients who did vs. did not receive ICDs
over a mean follow-up period of 34+16 months. Although both
the groupswere similar in age and prevalenceofmostmajor comorbid
conditions, ICD therapy was associated with a 31% lower risk for all-
cause mortality, a mortality benefit similar to those seen in primary
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Studies evaluating the safety of ICD implantation in the elderly
Study Study population Main findings
Tsai et al.31 † Primary prevention ICD recipients within the
US NCDR ICD Registry
† 150.264 patients (61% ≥ 65 years;
16.1% ≥ 80 years old)
† Occurrence of any peri-procedural adverse event or in-hospital death increased
from 2.8% in the youngest age group (,65 years) to 4.5% in the oldest age groups
(≥80 years)
† Renal failure, stage IV heart failure, atrial fibrillation, third degree heart block,
biventricular ICD placement, female gender, physician non-certification and device
implantation by non-electrophysiologists were stronger predictors of
complications than age
Yung et al.23 Registry of 5399 ICD recipients in Ontario,
Canada
† Rates of complications within 45 days of implantation: 18–49 years old – 7.5%;
70–79 years old – 7.6%; ≥80 years old – 10.7% (P ¼ ns)
Grimm et al.27 500 consecutive patients included in the
Marburg Defibrillator database
All procedure-related, lead-related, and pulse generator-related complications were
similar in both patient groups (23 vs. 25%) during follow-up of 48+39 months
Duray et al.32 375 consecutive ICD recipients with structural
heart disease
Device associated complications were comparable in both groups
(,70 vs. ≥70 years old)
Van Rees et al.33 1395 patients treated with a primary preventon
ICD
† Lower rate of inappropriate shocks in patients ≥75 years old
† Similar rate of different complications such as infection, lead failure, and lead
dislodgment in elderly patients (≥75 years old) vs. the other sub-groups
Reynolds et al.34 31.000 Medicare beneficiaries receiving ICDs in
2002–2003
Rate of one or more in-hospital complications related to ICD implantation was 10.8%
and age distribution was similar among patients who experienced complications
compared with those who did not
Al-Khatib et al.35 8581 patients aged ≥65 who received an ICD
between January 2002 and September 2005
Age was not an independent risk factor for increased complications
Noseworthy
et al.36
183 septuagenarian ICD recipients vs. 29
octogenarians
The complication rates at the time of ICD implantation were 6.6% in septuagenarians
and 13.1% in octogenarian, but difference was not statistically significant
ICD, Implantable cardioverter-defibrillator; CRT-D, cardiac resynchronization therapy defibrillator; US NCDR, United States National Cardiovascular Data Registry.
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prevention trials and that persisted after stratification by age (,65,
65–74, and ≥75). Implantable cardioverter-defibrillator therapy was
associatedwith comparable absolute and relativemortality risk reduc-
tions in elderly patients despite higher annual mortality rates.14 Com-
bining data from four RCTs (MUSTT, MADIT-II, DEFINITE, and
SCD-HeFT), Kong et al. reported that primary prevention ICD
therapy remains efficacious in reducing all-cause mortality in patients
≥75 years of age,12 contradicting a similar meta-analysis published 1
year before.17 A recent paper by Earley and associates supports the
benefit of the ICD in this age group.15
Evidence against cardioverter-defibrillator implantation in
the elderly
The benefit of the ICD in primary prevention of SCD, according to
MADIT II and SCD-HeFT, emerges only in a mid- to long-term
follow-up (2–5 years).16 Given that the median survival of elderly
patients with an ICD has been shown to be less than 5 years in
most studies,25,33,42,43 the effectiveness of the ICD in prolonging
their lives seemsmarginal. The SCD-HefT trial failed to demonstrate
improved survival in patients ≥65 years, and survival in the overall
cohort was essentially the same for ICD and non-ICD patients
alike for the first 18 months of follow-up.2 A meta-analysis by San-
tangeli et al had reported on pooled data of the DEFINITE,
SCD-HeFT, and MADIT trials, but was unable to demonstrate signi-
ficant survival benefit of the ICD in the elderly.17 A different meta-
analysis pooled individual patient data from all three secondary
prevention trials comparing ICD to amiodarone (AVID, CIDS and
CASH) and concluded that ICD therapy did not seem to offer a
survival benefit in secondary prevention patients ≥75 years of
age.18 The AVID trial showed an unadjusted average of only 2.7
months of additional life gained at 3 years in a cohort of patients
with mean age of 65.19
Selecting the patient for the
procedure: which elderly patients
to consider for an ICD?
A previous study has shown that there is no significant difference in
survival between clinical trial patients (MADIT-II and SCD-HeFT)
randomized to receive an ICD and a similar group of clinical registry
patientswho received a primary prevention ICD, despite the fact the
latter are significantly older and have more comorbidities. These
results held even after limiting the analyses to patients 65 years and
older. However, criticisms exist regarding the exclusion of many
patients from analysis, stating that the clinical registry subgroup did
not resemble a true cohort of patients in real-life practice.47
Although there are many elderly patients in whom implantation
of an ICD is not appropriate because of comorbidities that may
shorten life expectancy, Koplan et al.42 have shown that a proportion
of elderly patients may survive for ≥4 years after ICD implant. As
the low-ejection fraction group has considerable risk heterogeneity,
andmultiple parametersmay influence the risk of arrhythmicmortal-
ity amongpatientswith similar degreesof left ventricular dysfunction,
identification of those patients at high risk of earlymortalitywhomay
not derive any benefit from ICD implantation is essential for optimal
patient management. As ‘reasonable expectation of survival’ has
not been standardized, physicians ultimately rely on their clinical
judgement. How can life expectancy be determined in candidates
for an ICD implantation? Although age is a predictor of mortality, it
does not accurately identify patients who benefit vs. do not benefit
from the ICD when used in isolation. Additional parameters must
be taken into account. In this context, several risk stratification
scores have been proposed to estimate the risk of potential ICD
recipients48–53 (Table 3). Their findings must be taken into context
and mortality rates compared with those of the conventional
therapy groups of the MADIT-II (19.8% over a mean follow-up of
20 months)1 and SCD-HeFT trials (29% over a mean follow-up of
45.5 months).2
(i) A MADIT-II sub-study stratified primary prevention patients
based on the presence of five simple clinical parameters: age
.70 years, heart failure functional class .II, blood urea nitro-
gen.26 mg/dL,QRS duration.0.12 s, and atrial fibrillation.48
While patients with no risk factors were shown to experience
relatively low 2-year mortality rates without an ICD, thereby
limiting a meaningful ICD effect within this time period, very
high-risk patients (defined by urea levels ≥50 mg/dL and/or
serum creatinine ≥2.5 mg/dL) had 2-year mortality rates
close to 50%, with or without an ICD, and the predominant
mode of death in this population was non-arrhythmic in
nature. Implantable cardioverter-defibrillator therapy was
associated with a 49% reduction in the risk of death among
patients with one to two risk factors, while in patients with
three risk factors or more mortality was only slightly lower in
the ICD group than in the conventional therapy group (29 vs.
32%).48 This risk score was subsequently validated in a long-
term follow-up49 and a cohort of elderly patients.50
(ii) In their cohort of patients with an ICD, Chong et al.52 have
shown that those with clinical markers involving two or more
organ systems had a 38% 1-yearmortality rate despite the ICD.
(iii) Based on .45.000 primary prevention ICD patients (of which
40% were ≥75 years of age), Bilchick et al. developed a
model (‘SHOCKED’) that accurately identified patients at
highest risk of death after ICD implantation.53 In MADIT-II1
and SCD-HeFT,2 the 20%of patientswith the highest predicted
mortality rates after ICD implantation did not derive a survival
benefit from ICD implantation. With this in mind, it was note-
worthy that the 58% 3-year mortality rate for registry patients
in the highest nomogram-based quintile of risk53 was even
higher than the 3-year mortality rate for ICD patients in the
highest risk quintile (42%) from the SCD-HeFT analysis.2
(iv) The algorithm developed by Kraaier et al. comprised age ≥75
years, LVEF ≤20%, history of atrial fibrillation, and estimated
glomerular filtration rate (GFR) ≤30 mL/min/1.73 m2 and
was subsequently validated in a different cohort. Patients with
three or more risk factors had 1-year mortality of 38.9 and
46.3% in the derivation and validation cohorts, respectively.54
(v) Data fromMADIT-II have shownsevere renal dysfunction tobe
the most powerful predictor of all-cause mortality during the
course of the trial. While ICD therapy was associated with a
survival benefit in each GFR category of ≥35 mL/min/
1.73 m2, no benefit was shown among patients with a GFR of
,35 mL/min/1.73 m2.55 Although patients with renal
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dysfunction may be at higher risk of ICD therapies,56 there is
enough evidence suggesting that patientswith severe renal dys-
function do not get a survival benefit from the ICD.37,42,44,48,55
(vi) A more recent meta-analysis including 72 studies evaluating 63
mortality predictors in 257.692 ambulatory heart failure ICD
recipients identified strong mortality predictors in these
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Risk scores developed for the prediction of mortality in potential ICD recipients
Study Parameters included Main findings
Goldenberg et al.48—MADIT-II sub-study, primary
prevention patients
Barsheshet et al.49—Validation in long-term follow-up
Anne´et al.50—Validation in acohortof elderly patients
† Age .70 years
† NYHA class .II
† Blood urea nitrogen
.26 mg/dL
† QRS duration .0.12 s
† Atrial fibrillation
Crude mortality rates in the conventional group over a mean
period of 20 months were:
† ZERO risk factors – 9%
† ≥1 risk factors 228%
† Urea levels≥50 mg/dLand/or serumcreatinine≥2.5 mg/dL
– 43%
ICDtherapy associatedwith a 49%reduction in the riskof death
among patients with ≥1 risk factors, mostly among those
with 1 or 2 risk factors, whereas no benefit was seen in
patients with zero risk factors (HR 0.96) and in very-high risk
individuals (HR 1.0). Among patients with ≥3 risk factors,
mortalitywas only slightly lower in the ICD group than in the
conventional therapy group (29% vs. 32%).
While low-risk patientswere shown to experience relatively
low 2-year mortality rates without an ICD, very-high risk
patients had 2-year mortality rates close to 50%, with or
without an ICD.
Parkash et al.51
469 consecutive patients who underwent ICD
implantation at a single tertiary-care centre
† Age. 80 years
† History of atrial fibrillation
† Creatinine. 1.8 mg/dL
† NYHA class III or IV
One-year mortality significantly increased with increasing risk
score in both the prediction and validation cohorts.
Validation cohort mortality was:
† 3.4% for zero point
† 4.3% for one point
† 17% for two points
† 33% for three or more points
A risk score ≥2 predicted a 1-year mortality rate of 21%,
whereas a risk scoreof,2predicted amortality rateof 4%at
1 year.
Chong et al.52
283 patients with de novo ICDs implanted for primary
or secondary prevention in ischaemic heart disease
and dilated cardiomyopathy
† Liver dysfunctiona
† Respiratory dysfunctionb
† Renal dysfunctionc
† Anaemiad
† Prior cerebral vascular
injury
One-year mortality was:
† 1.9% with no organ dysfunction
† 14.3% with single organ dysfunction
† 38.1% with two or more markers of organ dysfunction
Bilchick et al.53
Approximately 45 000 Medicare beneficiaries
receiving primary prevention ICDs, ‘SHOCKED’
model
† ≥75 years of age
† NYHAClass III
† Atrial fibrillation
† Chronic obstructive
pulmonary disease
† Chronic kidney disease
† LVEF ≤ 20%
† Diabetes mellitus
This model had C-statistics of 0.75 (95%CI 0.75–0.76) and 0.74
(95% CI 0.74–0.75) in the development and validation
cohorts, respectively. Validationpatients in the highest decile
of risk (nomogramscore.246)hadmortality rates after1, 2,
and 3 years of 28, 44, and 65%, respectively.
Approximate 1-, 2-, and 3-yearmortality rates (respectively)
according to the quintile of risk:
† First quintile: 3, 7, 13%
† Second quintile: 4, 11, 21%
† Third quintile: 8, 15, 28%
† Fourth quintile: 13, 25, 40%
† Fifth quintile: 24, 39, 58%
Kraaier et al.54
861 prophylactic ICD recipients with ischaemic or
non-ischaemic DCM
† Age ≥75 years
† LVEF ≤ 20%
† History of atrial fibrillation
† GFR ≤ 30 mL/min/1.73 m2
A low (≤1 factor), intermediate (2 factors), and high (≥3
factors) risk group could be identified with 1-year mortality
of, respectively, 3.4, 10.9, and 38.9%.
Afterwards, the risk score was validated in 706 primary
prevention patients: 1-year mortality was 2.5, 13.2, and
46.3%, respectively
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction.
aAST or ALT ≥ 3× upper limit of normal or PT or INR ≥ 1.5 in the absence of anticoagulation.
bRecent mechanical ventilation within 3 months prior to ICD implant.
cCreatinine ≥150 mmol/L or GFR ≤30 mL/min/1.73 m2.
dHaemoglobin ≤100 g/L.
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patients:57 age, baseline GFR, chronic obstructive pulmonary
disease, diabetes, peripheral vascular disease, left ventricular
ejection fraction, and appropriateor inappropriate ICDshocks.
(vii) Different studies have confirmed the negative survival impact of
peripheral vascular disease,23,58 pulmonary disease,58 atrial fib-
rillation,59 and previous heart failure hospitalizations60 in ICD
recipients. In regards to heart failure, a study by Eho et al sug-
gested that womenwith this comorbidity have lower mortality
than men, and fewer of those deaths are sudden throughout a
spectrum of all-cause mortality risk.61
Procedural aspects: what device
and implantable
cardioverter-defibrillator
programming?
The use of a single-chamber device and ICD programming to
ventricular backup pacing at 40 b.p.m. should be strongly considered
should there be no indication for pacing.62,63 However, the need
to minimize right ventricular pacing is not age-specific. The
PREPARE,64 MADIT-RIT,30 and ADVANCE-III65 studies and two
very recentmeta-analyses66,67 have clearly shown that programming
high-rate and/or delayed therapy associates with reductions in un-
necessary ICDtherapyandmayeventually decrease all-causemortal-
ity.30 This may be relevant to the elderly population, as a subgroup
analysis of the MADIT-RIT trial suggested that patients .65 years
old had the largest survival benefit from high-rate ICD therapy.30
Also, a lower threshold forCRT implantationwithout defibrillator
backup in the primary prevention elderly patient should perhaps be
considered in light of recent evidence, suggesting that (i) CRT-D
does not offer additional survival advantage over CRT-P at longer
term follow-up, despite a trend at 1 year favouring the former;68
(ii) there is no survival benefit from CRT-D (vs. CRT-P) in patients
deemed non-responders to CRT,68 and (iii) the association
between advanced age and adverse clinical outcomes (heart failure,
death, and appropriate ICD therapy) is attenuated in elderly patients
implanted with CRT-D devices compared with ICD only.69 When
elderly patients with heart failure are at high risk of non-suddenmor-
tality because of a high comorbidity burden,70 a CRT-P device rather
than a CRT-D may be justified as symptomatic improvement
and enhanced QoL are probably more relevant than reducing the
risk of arrhythmic mortality. It should be noted that two previous
studies have suggested that catheter ablationof ventricular tachycardia
in elderly patients with structural heart disease is a relatively safe and
effective procedure.71,72 It is reasonable to consider VT ablation as
an alternative to the ICD in elderly patients who refuse ICD implant-
ation or whose life expectancy is limited.
Figure1highlights the frequent dilemmas involved in thedecision to
give elderly patients an ICD, while Figure 2 lists the main similarities
and differences between elderly patients and other age groups.
Implantable cardioverter-
defibrillator generator
replacement at the end of battery
life: is there any evidence of benefit
in the very elderly?
There are no current formal recommendations to guide physicians
when elderly patients with ICDs require elective unit replacement
(EUR).
Can we extrapolate the results of
trials supporting the guidelines to
this population?
Are there specific elderly groups
with higher benefit?
Some risk classifications have been proposed49–55,
but an ultimate score providing strong support for
implanting in some patients while excluding others 
is still lacking
How old is too old?
Neither this aspect, nor the issure of the existence
of a clear cutoff value for defining elderly and very
elderly have yet been clarified: inexistent
evidence
Is it cost-effective? For all patients?
ICDs are not cost-effective in elderly patients as a
 group, but may be a cost-effective therapy when
 the patient has a longevity of ≥7 years or one ICD
     battery life: moderate evidence85,86  
Is there a benefit from ICD replacement
at the end of battery life?
The benefit in elderly patients without previous
ICD therapies may be marginal:
weak evidence75,76
Is there a benefit from specific devices
and/or programming?
Therapy reduction programming results in
significant and consistent reduction in all-cause
mortality in the overall ICD population, but this
question has not been specifically addressed in
the elderly: weak evidence66
When should therapies be disabled?
This should occur after a combined patient and/or family
(if the patient is unable to decide) decision
Consensus / Not evidence-based
Does it improve survival?
Mortality is higher in elderly: 
strong evidence24,26,34,43,44
However, there may be a survival benefit in
selected individuals: weak evidence12–14
What is the risk of peri- and post-
procedural complications?
Similar or only slightly higher for peri-procedural:
strong evidence12,24,28,32,33–37
Not clear in the mid/long-term: lacking evidence
Use of ICDs in the elderly
Frequent dilemmas
what is the evidence?
Possibly: weak evidence48
Figure 1 Frequent dilemmas involved in the use of ICDs in the elderly. ICD, implantable cardioverter-defibrillator.
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In our analysis of all ICD-related procedures carried out in octo-
genarians at our hospital between November 1991 and May
2012,25 we reported the median additional years of life after ICD
EUR in patients who died before data retrieval was 1.2, and 50% of
deceased patients died within the first year. Ventricular tachycardia
occurred in a small minority of patients after EUR and no VF events
were reported. Importantly, ICD therapies were not delivered in
patients who had not had ICD interventions before the EUR.25 A
very recent study reported 1-, 3-, and 5-year mortality rates of 9.8,
27.0, and 41.2%, respectively, in 111.826 patients from the
NCDRw ICD RegistryTM following ICD generator replacement.
Older age, atrial fibrillation, congestive heart failure, chronic lung
disease, cerebrovascular disease, diabetes, and renal dysfunctionpre-
dicted worse survival.73 In a different study, at least 26% of 231
patients admitted for ICD generator replacement no longer met
guideline indications for an ICD (indications for continued ICD
therapy were defined as EF, 35% or receipt of appropriate device
therapy)74 and subsequently received appropriate ICD therapies at
a significantly lower annual rate compared with patients who did
(2.8 vs. 10.7%).74 These studies may question the applicability of
ICD generator replacement in very elderly patients with no history
of appropriate ICD therapies and support the need for re-evaluation
of the LV EF prior to unit replacement, and eventually perform ICD
explant, rather than generator replacement, in those without previ-
ous appropriate ICD therapies and with significant improvement of
LV systolic function. Importantly, the risk of appropriate ICD
therapy and/or rapid ventricular arrhythmia, albeit persisting over
time, decreases significantly over the years.75
In octogenarians who are due for an ICD EUR, several arguments
can be made for either:
Use of ICDs in the elderly
Points to consider
in decision-making
Are elderly similar to
other age groups?
Yes/May be No
• Similar rates of appropriate shocks24,29,33,34
• ICD therapies have similar effectiveness in terminating
  ventricular arrhythmias24,29
• ICDs remain effective in reducing all-cause mortality in very
  well selected patient (contradicting results)12–14
• Similar rates of peri- and post- procedural complications
  (contradicting results)12,24,28,33–37
• They have been underrepresented in most RCTs1–7,20,21
• Higher prevalence of comorbidities
• Higher prevalence of chronic kidney disease, a strong predictor 
  of all-cause mortality in several ICD trials38,43,45,49,56
• Higher relative contribution on nonarrhythmic causes of death18,27,29
• Appropriate therapies may occur more frequently preceding 
  non-arrhythmic death, not impacting on overall survival18
• Higher peri-procedural complication rates (contradicting results)32
• Lower rate of inappropriate shocks24,34
• Lower life expectancy24,26,34,43,44
• ICDs seem ineffective or only marginally effective in reducingall-cause
  mortality in the elderly, as a group (contradicting results)2,16,17,18,26,34,43–45
• Patient selection and comorbidity assessment may play a much more
  important role
• Longevity of leads may be a less important issue (give the lower life
  expectancy of the elderly patient)
• May need backup pacing more frequently
• One battery-life may be enough in most patients (as average median
  survival does not exceed 5 years in most studies)26,34,43,44
• Elderly may benefit from less aggressive ICD programming (inference,
  give their higher degree of comorbidity and frailty)65–69
• They seem to value quality of life over longevity42
• Ethical issues when performing elective generator replacement
• ICDs may interfere with the natural process of dying peacefully83
• Elderly more frequently demand therapy deactivtion when
  approaching the end of life
• ICDs may be less cost-effective, namely if the patient does not outlive
  the battery85,86
Figure 2 Use of ICDs in the elderly: points to consider in decision-making. ICD, implantable cardioverter-defibrillator; RCT, randomized con-
trolled trial.
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Downgrading the implantable
cardioverter-defibrillator to a standard
pacemaker (if pacing support needed),
explanting the device or simply not
replacing it at all
Mortality is high in the first few years following ICD generator re-
placement.25,73 Patients who demonstrate recovery of LV function
fromCRTormedical therapymaybeat lower riskof arrhythmicmor-
tality when compared with the pre-procedural estimated risk76 and
the absence of complex ventricular arrhythmias or appropriate
ICD therapies since initial ICD implantation may be a surrogate for
lower arrhythmic risk. Although the INSURE trial77 reported that
21.4% of ICD patients without prior appropriate ICD therapy still
received appropriate ICD intervention within 3 years of generator
replacement, the vastmajority of devices had been initially implanted
for secondary prevention in the 1990s, well before the publication of
studies showing that programming high-rate and/or delayed therapy
associates with reductions in unnecessary ICD therapy.30,64,65 We
should also remember that ICD generator replacement implies a
4–6% riskofmajor peri- and post-procedural complications,78–80 al-
though it is not clear whether elderly patients are at higher risk of
complications. A recent study has shown that more than one-third
of 125 deceased patients had ventricular tachyarrhythmia events
with shocks within the last hour of life, with half of them receiving
three or more shocks. Sixty-five per cent of patients with a do-not-
ICD generator replacement in the elderly
Points to consider
in decision-making
In octogenarians due for an ICD
generator replacement, several
arguments can be made for either
Replacing the device generator
• Unless requested by the patient, it would be unethical not
  to replace the ICD generator at end of battery life in elderly
  patients with previous appropriate ICD therapy for VF or
  fast VT 
• Some ICD patients whose EF has improved to >35% at the
  time of generator replacement remain at risk for
  appropriate ICD shocks84
• More than one fifth of ICD patients without prior
  appropriate ICD therapy still receive appropriate ICD
  intervention whithin 3 years of generator replacement79
• As some individuals get used to a psychological sense of
  security from their device, they may find it traumatizing to
  manage without it
• Future treatments developed for heart failure and other
  non-cardiac medical conditions may eventually reduce
  their risk of non-sudden death
Downgrading the ICD to a standard pacemaker
(if pacing support is needed) or simply not
replacing it at all 
• High mortality rates in the first few years following ICD generator
  replacement, especially in those with multiple comorbidities26,75
• At least ¼ of patients no longer meet guideline indications for an
  ICD at time of unit replacement. These patients subsequently
  receive appropriate ICD therapies at a significantly lower annual
  rate76
• Patients who demonstrate recovery of LV function from CRT or
  medical therapy may be at lower risk of arrhythmic mortality when
  compared to the pre-procedural estimated risk77
• The risk of appropriate ICD therapy and/or rapid ventricular
  arrythmia, albeit persisting over time, decreases significantly
  over the years77
• With increasing age, some patients may feel differently towards
  their final mode of death and may wish to have their device
  deactivated
• ICD generator replacement implies a 4–6% risk of major peri- and
  post-procedural complications80–82
• ICDs may interfere with the natural process of dying peacefully83
• ICD generator replacement in the elderly, as a group, is hardly
  cost-effective85,86
Figure 3 Implantable cardioverter-defibrillator generator replacement in the elderly: points to consider in decision-making. ICD, implantable
cardioverter-defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia; LV, left ventricular; CRT, cardiac resynchronization therapy.
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resuscitate order still had shock therapy programmed ‘on’ at 24 h
before death, which allowed for the delivery of shock treatment in
almost one-fourth of them (Figure 3).81
Replacing the device generator
It would be unethical not to replace the ICD generator at end of
battery life in elderly patients with previous appropriate ICD
therapy for VF or fast VT, unless requested by the patient. Some
ICD patients whose EF has improved to .35% at the time of ICD
generator replacement remain at risk for appropriate ICD shocks82
and up to 21.4% of ICD patients without prior appropriate ICD
therapy may still receive appropriate ICD intervention within 3
years of generator replacement (Figure 3).77
Cost-effectiveness: is it
cost-effective to give elderly
patients an implantable
cardioverter-defibrillator?
With the expansion of the population eligible for an ICD, resource
limitations and discussions of cost-effectiveness have come to the
forefront. The cost-effectiveness of the ICD in routine clinical prac-
tice seems less obvious in certain sub-groups of patients, particularly
in the caseof elderlypatientswhoareathigher riskof non-arrhythmic
death.
As most costs associated with ICD implantation occur in the early
phase of treatment, cost-effectivenessmay becomemore favourable
as patients live longer, the battery life of ICDs extends, cost of the
device is reduced and improvements to efficacy occur (improved
patient selection, minimized unnecessary shock). Patient longevity
increases the cost-effectiveness of the ICD. In the MADIT-II trial,1
the number needed to treat to prevent one additional primary
outcome decreased from 17 at the end of the first 2 years to 8
when follow-up was extended to 8 years.
On the basis of data from eight large primary prevention trials, the
incremental cost-effectiveness of prophylactic ICD therapy has been
estimated to range from $34.000 to $70.200 per quality-adjusted life
year (QALY) added.83 The authors claimed that costs would remain
,$100 000perQALYas long asmortalitywas reduced for≥7 years,
with estimated costs escalating quickly as the duration of efficacywas
reduced. If the survival time horizonwas reduced to 5 years after ICD
implantation, as in patients ≥75 years described by Pelligrini et al.,43
cost estimates would vary between $90.000 and $250.000. Though
a single threshold for cost-effectiveness has not been properly estab-
lished, values ranging from$50.000 to$120.000perQALYhavebeen
proposed.84 In this context, it is highly relevant that the average
median survival of elderly ICD recipients (≥75 years old) does
not seem to surpass the 5-year mark in most studies,25,33,42,43 with
much shorter lifespan in patients with multiple comorbidities. In
fact, current data do not support the assumption that ICD therapy
has a persistent effect on late survival. A meta-analysis of secondary
prevention trials showed a convergence of survival curves for ICD
and control arms at 4 years and a life extension of just 4.4 months
over a follow-up period of 6 years,85 while patients receiving
appropriate shocks in the SCD-HeFT and MADIT-II studies had a
poor short-termprognosis.86,87 In the latter, basedonan average sur-
vival gain of only 2months and a three-fold higher rate of hospitaliza-
tions, the incremental cost-effectiveness ratio was $235.000 per year
of life saved, unadjusted for QoL.88 A similar finding was reported
from theCIDS trial in secondary prevention.89 Thus, ICD intervention
among the elderly, as a group,may not be cost-effective. To reach cost-
effectiveness in the elderly, limiting their application to those expected
to live .5 years after implantation, or rather one ICD battery-life,
would be necessary.
An important aspect of cost-effectiveness is the assessment of the
impactonQoL. In the caseof ICDtherapy, evidence remains conflict-
ing and relatively weak. The only study examining the relationship
between age and QoL in the setting of a RCT was a MADIT-II sub-
study that found no significant differences in QALY between
control and ICD groups and between patients younger and older
than 65.90 The largest QoL study in ICD recipients for primary pre-
vention of SCD was performed in the SCD-HeFT population, yet
the effect of age on QoL was not examined. In fact, there is little
QoL data on the use of ICDs in elderly patients, which is a paradox
as QoL is often a critical factor in clinical decision-making in the
elderly. However, while older patients with ICDs have decreased
physical functioning, more co-morbid illness, and worse symptoms
thatnegatively impactQoL,youngerpatientswith ICDstendtoexperi-
ence increased psychological distress, anxiety, and depression.91,92
Implantable cardioverter-defibrillator impact on QoL goes much
beyond the deleteriously impact of recurrent or unnecessary shocks.
Reynolds et al.34 found one or more complications in 11% of the pro-
cedures which were associated with highly significant increase in the
length of hospital stay (1–10 days) and hospital costs ($5.000–
$20.000). Also, recent data suggest that device-related infection
increased by 1% in the last decade, reaching 2.41% of all implants in
2008.93 The hospitalization of elderly patients tends to be more pro-
longed and susceptible to clinical intercurrences and thusmore costly.
Conclusions
Implantablecardioverter-defibrillator implantationmayreducemortal-
ity in the elderly, but it should be recognized to constitute a smaller
absolute clinical benefit. Termination of ventricular arrhythmias by
ICD therapies could prevent sudden death, but probably results in a
marginal prolongation of life, due to high competing risk for non-
SCD. Alongside with the expensive cost, the possibility of adversely
affecting QoL and increasing comorbidity burden may lead to difficul-
ties in justifying this therapy in the elderly population. Nevertheless,
in those very well-selected elderly patients at high risk of arrhythmic
death and with minimum comorbidities despite advanced age, ICD
interventionmay reducemortality to near age-specific life-expectancy.
Therefore, biological age (possibly assessed through a multivariable
score, which is yet to be optimized) rather than chronological age
per se should be the decisive factor in making a decision on ICD selec-
tion for survival benefit.
Conflict of interest: none declared.
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Simplified mapping and ablation of a scar-related atrial tachycardia using
magnetic resonance imaging tissue characterization
Felipe Bisbal*, David Andreu, and Antonio Berruezo
Arrhythmia Section, Cardiology Department, Thorax Institute, Hospital Clı´nic, C/ Villarroel 170-08036, Barcelona, Catalonia, Spain
* Corresponding author. Tel: +34 93 2275551; fax: +34 93 4513045; E-mail address: f.bisbalvb@gmail.com
A 32-year-old woman with atypical atrial flutter was referred for a
first-ever ablation. A preprocedural delayed-enhancement cardiac
magnetic resonance (DE-CMR)was performed; the three-dimensional
reconstruction of left atriumdepicting the healthy (purple) and scarred
myocardium (red) was imported into the navigation system to guide
the ablation. A counterclockwise perimitral activation sequence was
identified (panel A).
The substrate characterization provided by DE-CMR facilitated the
identification of an anatomical isthmus at the inferior aspect of the left
atrium (panels B and C), between a large, scarred area at the posterior
wall (asterisk) and the inferior mitral annulus (black arrowheads). The
integrated DE-CMR reconstruction allowed catheter positioning and
limited mapping at this site; a continuous, fractionated signal—highly
suggestive of a protected, slow-conducting isthmus—was identified.
Radiofrequency application at this site terminated the arrhythmia.
No further arrhythmias could be induced.
The standard ablation approach of a perimitral flutter includes ex-
tensive ablation at themitral isthmus to create a lineof block; in patients
without prior AF ablation, additional encircling lesions around the left-
sided pulmonary veins are required. In this case,DE-CMRwas crucial in
identifying the critical isthmus of the circuit; this allowed limited mapping to the area of interest and limited energy delivery.
The full-length version of this report can be viewed at: http://www.escardio.org/communities/EHRA/publications/ep-case-reports/
Documents/Simplified-mapping-and-ablation.pdf.
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2014. For permissions please email: journals.permissions@oup.com.
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